20 May 2013
Keywords: austcancer, buy, galencia, 5m, australian, cancer, technology
Article | 31 May 2004
Australian Cancer Technology has signed a deal to acquire, via its wholly-owned US subsidiary Adjuvantys, the business of Galencia
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 May 2004
17 May 2013
© 2013 thepharmaletter.com